Market Analysis
Novo Nordisk Shares Rise After FDA Pressures Hims to Pull Weight-Loss Pill
Novo Nordisk stock jumped 8% after Hims & Hers withdrew its knockoff Wegovy pill amid FDA scrutiny and legal threats.
BTC$62,423.00-0.16%
ETH$1,660.95+0.09%
USDT$0.99870.00%
USDC$0.9998+0.01%
XRP$1.09-2.08%
SOL$68.95-0.35%
TRX$0.3309+0.49%
FIGR_HELOC$1.03-0.15%
HYPE$61.92-1.53%
DOGE$0.0783-1.44%
USDS$0.9995-0.01%
RAIN$0.016+1.42%
LEO$9.54+0.12%
ZEC$412.09-2.99%
XLM$0.1902-1.48%
BTC$62,423.00-0.16%
ETH$1,660.95+0.09%
USDT$0.99870.00%
USDC$0.9998+0.01%
XRP$1.09-2.08%
SOL$68.95-0.35%
TRX$0.3309+0.49%
FIGR_HELOC$1.03-0.15%
HYPE$61.92-1.53%
DOGE$0.0783-1.44%
USDS$0.9995-0.01%
RAIN$0.016+1.42%
LEO$9.54+0.12%
ZEC$412.09-2.99%
XLM$0.1902-1.48%
Hims & Hers stock jumped more than 7% in premarket trading after the company agreed to acquire digital health platform Eucalyptus in a deal worth up to $1.15 billion.
Novo Nordisk stock jumped 8% after Hims & Hers withdrew its knockoff Wegovy pill amid FDA scrutiny and legal threats.
Hims & Hers stock rose over 10% after the company unveiled plans to sell a cheaper compounded version of Novo Nordisk’s Wegovy pill.
Novo Nordisk ended its month-old partnership with Hims & Hers Health over illegal drug compounding practices.